SuperworthUnicycive Therapeutics revenue UNCY
Sales by quarter and over the last twelve months, from 2022.
- Last 12 months, to Dec 31, 2023
- $675K
- Latest quarter, Q4 FY23
- $0
- Fiscal year 2023
- $675K
Unicycive Therapeutics' revenue was $675K over the twelve months to Dec 31, 2023.
In its latest quarter, Q4 FY23, it was $0.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2023 | $675K | n/a |
| FY2022 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY23 | $0 | n/a | $675K | |
| Q3 FY23 | $0 | −100% | $675K | |
| Q2 FY23 | $0 | n/a | $1.6M | |
| Q1 FY23 | $675K | n/a | n/a | |
| Q4 FY22 | $0 | n/a | n/a | |
| Q3 FY22 | $951K | n/a | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Unicycive Therapeutics' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| UNCYUnicycive Therapeutics | n/m | |
| LFVNLifevantage | $182.6M | −20% a year |
| SPROSpero Therapeutics | $47M | −3% a year |
| NATRNatures Sunshine Products | $492M | +7% a year |
| ATNMActinium Pharmaceuticals | n/m | |
| ARVNArvinas | $316.7M | −15% a year |
| PBYIPuma Biotechnology | $231.2M | −3% a year |
| IRWDIronwood Pharmaceuticals | $389.3M | +26% a year |
| ZVRAZevra Therapeutics | $136.1M | +119% a year |
| CRMDCorMedix | $462.2M | +281% a year |
| COLLCollegium Pharmaceutical | $808.2M | +14% a year |
| Peer median | $316.7M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Unicycive Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.